n-methylaspartate has been researched along with Huntington Disease in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 9 (21.95) | 18.2507 |
| 2000's | 17 (41.46) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Burtscher, J; Di Pardo, A; Maglione, V; Millet, GP; Schwarzer, C; Zangrandi, L | 1 |
| Betuing, S; Boussicault, L; Caboche, J; Kacher, R; Lamazière, A; Potier, MC; Vanhoutte, P | 1 |
| Alberch, J; Brito, V; del Toro, D; Ginés, S; Giralt, A; Puigdellívol, M | 1 |
| Fan, J; Leavitt, BR; Lu, G; Park, KH; Raymond, LA | 1 |
| Hayden, MR; Kolodziejczyk, K; Parsons, MP; Raymond, LA; Southwell, AL | 1 |
| Beste, C; Humphries, M; Saft, C | 1 |
| André, VM; Deng, Y; Figueroa, BE; Friedlander, R; Graham, RK; Hayden, MR; Joshi, P; Leavitt, BR; Levine, MS; Lu, G; Metzler, M; Pouladi, MA; Raymond, L; Slow, EJ; Wu, NP | 1 |
| Armida, M; Domenici, MR; Ferrante, A; Ferretti, R; Martire, A; Pézzola, A; Popoli, P; Potenza, RL | 1 |
| Lukács, A; Papp, A; Szabó, A; Vezér, T | 1 |
| Alberch, J; Canals, JM; del Toro, D; Humbert, S; Pol, A; Saudou, F; Xifró, X | 1 |
| Bissada, N; Carroll, J; Cowan, C; Deng, Y; Faull, RL; Graham, RK; Gray, M; Hayden, MR; Metzler, M; Pouladi, MA; Raymond, LA; Vaid, K; Wang, L; Yang, XW | 1 |
| Alaghband, Y; Ando, TK; André, VM; Cepeda, C; Cummings, DM; Hickey, MA; Hong, SC; Joshi, PR; Levine, MS; Watson, JB; Zhu, C | 1 |
| Fan, J; Gladding, CM; Kaufman, AM; Milnerwood, AJ; Raymond, LA; Wang, L; Zhang, LY | 1 |
| Camacho, A; Hardingham, GE; Martel, MA; Puddifoot, C; Soriano, FX; Vidal-Puig, A; Wyllie, DJ | 1 |
| Chiodi, V; Domenici, MR; Ferrante, A; Martire, A; Pepponi, R; Popoli, P | 1 |
| Chase, TN; Farmer, C; Gillespie, M; Morris, MJ; Mosby, K; Verhagen Metman, L; Wuu, J | 1 |
| Choi, DW; Lee, CS; Macdonald, ME; Moss, JL; Revilla, FJ; Snider, BJ; Wheeler, VC | 1 |
| Beal, MF; Browne, S; D'Mello, S; Ferrante, RJ; Hewett, S; Kristal, BS; Kubilus, JK; Langley, B; Lee, J; Lu, P; Ratan, RR; Rubinsztein, DC; Ryu, H; Smith, K; Stavrovskaya, IG; Sugars, KL | 1 |
| Cano, J; Machado, A; Rite, I; Venero, JL | 1 |
| André, VM; Cepeda, C; Chandler, SH; de Lima, M; Levine, MS; Starling, AJ | 1 |
| André, VM; Cepeda, C; Gomez, Y; Levine, MS; Venegas, A | 1 |
| Bertram, L; Bissada, N; Deng, Y; Doty, CN; Graham, RK; Haigh, B; Hayden, MR; Leavitt, BR; Lu, G; Murphy, Z; Nicholson, DW; Pearson, J; Raymond, LA; Roy, S; Shehadeh, J; Slow, EJ; Warby, SC; Wellington, CL | 1 |
| Baimbridge, KG; Church, J; Fernandes, HB; Hayden, MR; Raymond, LA | 1 |
| Alberch, J; Del Toro, D; García-Martínez, JM; Pérez-Navarro, E; Xifró, X | 1 |
| Ilivitsky, V; Jones, BD; Mohr, E; Purdon, SE | 1 |
| Bernardi, G; Calabresi, P; De Murtas, M; Mercuri, NB; Pisani, A; Sancesario, G; Stefani, A | 1 |
| Albin, RL; Kremer, B; Tallaksen-Greene, SJ | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Marfia, GA; Pisani, A; Sancesario, G | 1 |
| Brundin, P; Castilho, RF; Hansson, O; Leist, M; Nicotera, P; Petersén, A | 1 |
| Brundin, P; Hansson, O; Haraldsson, B; Nicniocaill, B; O'Connor, WT | 1 |
| Chen, N; Hayden, MR; Lee, AT; Moshaver, A; Raymond, LA; Wellington, CL; Zeron, MM | 1 |
| Bernardi, G; Bonsi, P; Borrelli, E; Calabresi, P; Centonze, D; Greengard, P; Gubellini, P; Hipskind, RA; Picconi, B; Pisani, A | 1 |
| Cattaneo, E; Sipione, S | 1 |
| Ariano, MA; Calvert, CR; Cepeda, C; Chandler, SH; Flores-Hernández, J; Hayden, MR; Leavitt, BR; Levine, MS | 1 |
| Brundin, P; Chen, N; Hansson, O; Hayden, MR; Leavitt, BR; Raymond, LA; Wellington, CL; Zeron, MM | 1 |
| Beal, MF; Finn, SF; Kowall, NW; Mazurek, MF; Storey, E | 1 |
| Dure, LS; Penney, JB; Young, AB | 1 |
| Albin, RL; Anderson, KD; Balfour, R; Handelin, B; Markel, DS; Penney, JB; Reiner, A; Tourtellotte, WW; Young, AB | 1 |
| Jhamandas, K; Ruzicka, BB | 1 |
| Gray, PN; May, PC | 1 |
| Choi, DW; Koh, JY; Peters, S | 1 |
2 review(s) available for n-methylaspartate and Huntington Disease
| Article | Year |
|---|---|
A Rationale for Hypoxic and Chemical Conditioning in Huntington's Disease.
Topics: Brain; Cell Hypoxia; Humans; Huntington Disease; Mitochondria; N-Methylaspartate; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Signal Transduction; Sphingosine | 2021 |
Huntington's disease: pathogenesis, diagnosis and treatment.
Topics: Adult; Brain; Cognition Disorders; Diagnostic Imaging; Eye Movements; Female; Fetal Tissue Transplantation; Humans; Huntington Disease; Male; N-Methylaspartate; Neuropsychological Tests; Palliative Care | 1994 |
1 trial(s) available for n-methylaspartate and Huntington Disease
| Article | Year |
|---|---|
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Topics: Adult; Aged; Amantadine; Chorea; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Male; Middle Aged; N-Methylaspartate; Treatment Outcome | 2002 |
38 other study(ies) available for n-methylaspartate and Huntington Disease
| Article | Year |
|---|---|
CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content.
Topics: Animals; Cholesterol; Cholesterol 24-Hydroxylase; Corpus Striatum; Female; Homeostasis; Humans; Huntingtin Protein; Huntington Disease; Male; Membrane Microdomains; Mice; Mutation; N-Methylaspartate; Neurons; Receptors, N-Methyl-D-Aspartate | 2018 |
Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Line; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Gene Knock-In Techniques; Humans; Huntingtin Protein; Huntington Disease; JNK Mitogen-Activated Protein Kinases; Mice; N-Methylaspartate; Nerve Tissue Proteins; Nuclear Proteins; Okadaic Acid; Phosphorylation; Protein Binding; Protein Phosphatase 1; Proto-Oncogene Proteins c-akt; Putamen; Receptor, Nerve Growth Factor; Receptor, trkB; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; N-Methylaspartate; Neurons; Neurotoxins; Phosphotransferases | 2012 |
Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; CA1 Region, Hippocampal; Cell Membrane; Disease Models, Animal; Excitatory Postsynaptic Potentials; Hippocampus; Humans; Huntington Disease; Long-Term Potentiation; Mice; Mice, Transgenic; N-Methylaspartate; Neostriatum; Neuronal Plasticity; Neurons; Pyramidal Cells; Synapses | 2014 |
Striatal disorders dissociate mechanisms of enhanced and impaired response selection - Evidence from cognitive neurophysiology and computational modelling.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Cognition Disorders; Computer Simulation; Contingent Negative Variation; Corpus Striatum; Decision Making; Discrimination, Psychological; Electroencephalography; Excitatory Amino Acid Agonists; Female; Humans; Huntington Disease; Male; Models, Neurological; N-Methylaspartate; Nerve Net; Neurons; Neuropsychological Tests; Young Adult | 2014 |
Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Dendritic Spines; Disease Models, Animal; Disease Progression; Genetic Predisposition to Disease; Huntington Disease; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Degeneration; Neurotoxins; Organ Culture Techniques; Phenotype; Quinolinic Acid; Stress, Physiological; Synaptic Membranes; Synaptic Potentials; Synaptic Transmission | 2009 |
Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Corpus Striatum; Disease Models, Animal; Female; Huntington Disease; In Vitro Techniques; Male; Mice; Mice, Transgenic; N-Methylaspartate; Neuronal Plasticity; Neurotoxins; Pyrimidines; Receptor, Adenosine A2A; Receptor, trkB; Receptors, N-Methyl-D-Aspartate; Triazoles | 2010 |
Altered open field behavior in rats induced by acute administration of 3-nitropropionic acid: possible glutamatergic and dopaminergic involvement.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Agents; Huntington Disease; Male; Motor Activity; N-Methylaspartate; Nitro Compounds; Propionates; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Glutamate; Sulpiride | 2009 |
Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease.
Topics: Animals; Anticholesteremic Agents; beta-Cyclodextrins; Brain; Caveolin 1; Cell Membrane; Cell Survival; Cells, Cultured; Cholesterol; DNA; Excitatory Amino Acid Agonists; Fluorescent Antibody Technique; Homeostasis; Humans; Huntingtin Protein; Huntington Disease; Indicators and Reagents; Membrane Microdomains; Mice; Mice, Transgenic; N-Methylaspartate; Neostriatum; Nerve Tissue Proteins; Nuclear Proteins; Simvastatin; Transfection; Triglycerides | 2010 |
Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Caspase 6; Corpus Striatum; Disease Progression; Humans; Huntingtin Protein; Huntington Disease; Immunohistochemistry; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins | 2010 |
A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Topics: Analysis of Variance; Animals; Body Weight; Corpus Striatum; Disease Models, Animal; Disease Progression; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Exploratory Behavior; Genetic Predisposition to Disease; Genotype; Humans; Huntingtin Protein; Huntington Disease; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Muscle Strength; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Patch-Clamp Techniques; Phenotype; Rotarod Performance Test; Seizures; Trinucleotide Repeat Expansion | 2012 |
P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Topics: Analysis of Variance; Animals; Animals, Newborn; Apoptosis; Bacterial Proteins; Cerebral Cortex; Chromosomes, Artificial, Yeast; Coculture Techniques; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Guanylate Kinases; Humans; Huntingtin Protein; Huntington Disease; Immunoprecipitation; In Situ Nick-End Labeling; Luminescent Proteins; Membrane Proteins; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Peptides; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions | 2012 |
PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity.
Topics: Animals; Cell Death; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Female; Gene Knockdown Techniques; Huntingtin Protein; Huntington Disease; Male; Membrane Potentials; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA-Binding Proteins; Transcription Factors | 2012 |
BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Female; Genotype; Huntington Disease; Male; Mice; Mice, Inbred C57BL; N-Methylaspartate; Patch-Clamp Techniques; Receptor, Adenosine A2A; Synaptic Transmission | 2013 |
Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults.
Topics: Animals; Apoptosis; Cell Culture Techniques; Gene Expression; Genotype; Huntingtin Protein; Huntington Disease; Immunoblotting; Immunohistochemistry; Kainic Acid; Mice; Mice, Transgenic; N-Methylaspartate; Neocortex; Nerve Tissue Proteins; Neurons; Neurotoxins; Nuclear Proteins; Oxidative Stress; Peptides; Trinucleotide Repeat Expansion | 2003 |
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cells, Cultured; Gene Silencing; Humans; Huntingtin Protein; Huntington Disease; In Vitro Techniques; Lysine; Male; Methylation; Mice; Mice, Transgenic; Mitochondria, Liver; Motor Activity; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Plicamycin; Rats; Rats, Inbred BN; Rats, Inbred F344; Receptors, Glutamate; Transcription, Genetic | 2004 |
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denervation; Disease Models, Animal; Down-Regulation; Female; Glutamate Decarboxylase; Glycine; Huntington Disease; N-Methylaspartate; Neural Pathways; Neurons; Neurotoxins; Proto-Oncogene Proteins c-fos; Quinolinic Acid; Rats; Rats, Wistar; Receptor, trkB; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2005 |
Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Drug Resistance; Excitatory Amino Acid Agonists; Humans; Huntingtin Protein; Huntington Disease; Magnesium; Membrane Potentials; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 2005 |
Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Barium; Benzothiadiazines; Cerebral Cortex; Disease Models, Animal; Exons; Huntington Disease; Magnesium; Mice; Mice, Transgenic; N-Methylaspartate; Patch-Clamp Techniques; Pyramidal Cells; Receptors, Glutamate; Time Factors | 2006 |
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
Topics: Active Transport, Cell Nucleus; Animals; Brain; Caspase 6; Caspases; Cell Nucleus; Humans; Huntingtin Protein; Huntington Disease; Hydrolysis; Mice; Mice, Transgenic; Mutation; N-Methylaspartate; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Quinolinic Acid; Staurosporine | 2006 |
Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
Topics: Animals; Apoptosis; Bongkrekic Acid; Calcium; Calcium Signaling; Cells, Cultured; Cyclosporine; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluorescent Dyes; Huntington Disease; Ionophores; Mice; Mice, Neurologic Mutants; Mitochondria; N-Methylaspartate; Neurotoxins; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate; Trinucleotide Repeat Expansion | 2007 |
Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
Topics: Animals; Calcineurin; Cell Death; Cell Line, Transformed; Cell Survival; Cells, Cultured; Corpus Striatum; Huntingtin Protein; Huntington Disease; Mice; Mice, Inbred C57BL; Mutation; N-Methylaspartate; Nerve Tissue Proteins; Nuclear Proteins | 2008 |
Vulnerability of medium spiny striatal neurons to glutamate: role of Na+/K+ ATPase.
Topics: Animals; Brain; Corpus Striatum; Dose-Response Relationship, Drug; Energy Metabolism; Glutamic Acid; Huntington Disease; N-Methylaspartate; Neurons; Ouabain; Rats; Rats, Wistar; Sodium-Potassium-Exchanging ATPase | 1995 |
AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: implications for Huntington's disease.
Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Glutamates; Glutamic Acid; Humans; Huntington Disease; Hypothalamic Area, Lateral; Ibotenic Acid; Kainic Acid; Middle Aged; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate | 1993 |
Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Cholinergic Fibers; Corpus Striatum; Electrophysiology; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Huntington Disease; Interneurons; Kainic Acid; Membrane Potentials; N-Methylaspartate; Neurotoxins; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1998 |
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
Topics: Animals; Biomarkers; Brain; Cell Count; Cell Survival; Corpus Striatum; Exons; Humans; Huntington Disease; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Tissue Proteins; Neurotoxins; Quinolinic Acid; Receptors, N-Methyl-D-Aspartate | 1999 |
Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; gamma-Aminobutyric Acid; Glutamic Acid; Huntington Disease; Mice; Mice, Transgenic; Microdialysis; N-Methylaspartate; Neurotransmitter Agents; Potassium Chloride | 2001 |
Mutant huntingtin enhances excitotoxic cell death.
Topics: Apoptosis; beta-Galactosidase; Cell Death; Cell Line; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Genes, Reporter; Green Fluorescent Proteins; Humans; Huntingtin Protein; Huntington Disease; Kidney; Luminescent Proteins; Mutation; N-Methylaspartate; Nerve Tissue Proteins; Nuclear Proteins; Peptide Fragments; Protein Isoforms; Receptors, N-Methyl-D-Aspartate; Transfection | 2001 |
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.
Topics: Animals; Calcium Channel Blockers; Chelating Agents; Corpus Striatum; Dopamine; Electric Stimulation; Electron Transport Complex I; Electron Transport Complex II; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Huntington Disease; In Vitro Techniques; Interneurons; Long-Term Potentiation; Membrane Potentials; Methylmalonic Acid; Mice; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multienzyme Complexes; N-Methylaspartate; NADH, NADPH Oxidoreductases; Neurons; Nitro Compounds; Oxidoreductases; Propionates; Pyramidal Cells; Rats; Rats, Wistar; Succinate Dehydrogenase; Synaptic Transmission; Uncoupling Agents | 2001 |
Modeling Huntington's disease in cells, flies, and mice.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Caenorhabditis elegans; Cell Line, Transformed; Cells, Cultured; Corpus Striatum; Cysteine Endopeptidases; Disease Models, Animal; Drosophila melanogaster; Embryonic and Fetal Development; Fetal Proteins; Genes, Dominant; Genes, Lethal; Haplorhini; Humans; Huntingtin Protein; Huntington Disease; Kidney; Mice; Mice, Knockout; Mice, Transgenic; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; PC12 Cells; Peptide Fragments; Protein Interaction Mapping; Rats; Trinucleotide Repeats | 2001 |
NMDA receptor function in mouse models of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Calcium Channels; Calcium Signaling; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Huntington Disease; Immunohistochemistry; Ion Channels; Membrane Potentials; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Mutation; N-Methylaspartate; Neostriatum; Neurons; Organ Culture Techniques; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 2001 |
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
Topics: Animals; Caspase 3; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; In Situ Nick-End Labeling; In Vitro Techniques; Mice; Mice, Transgenic; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate | 2002 |
The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.
Topics: Age Factors; Aged; Animals; Aspartic Acid; Brain Chemistry; Cholecystokinin; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Glutamine; Humans; Huntington Disease; Male; Middle Aged; N-Methylaspartate; Neurochemistry; Rats; Rats, Sprague-Dawley; Somatostatin; Substance P | 1992 |
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
Topics: Adolescent; Adult; Age Factors; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Binding, Competitive; Caudate Nucleus; Cell Death; Child; Dizocilpine Maleate; Frontal Lobe; Glycine; Humans; Huntington Disease; Ibotenic Acid; Kainic Acid; Middle Aged; N-Methylaspartate; Phencyclidine; Receptors, AMPA; Receptors, Glutamate; Receptors, Glycine; Receptors, Kainic Acid; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Receptors, Phencyclidine | 1991 |
Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease.
Topics: Adult; Aspartic Acid; Corpus Striatum; Female; Heterozygote; Humans; Huntington Disease; Immunohistochemistry; N-Methylaspartate; Neurons; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Substance P; Suicide | 1990 |
Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins.
Topics: Animals; Corpus Striatum; Enkephalin, Methionine; Globus Pallidus; Huntington Disease; Injections; Kainic Acid; Male; N-Methylaspartate; Neurotoxins; Quinolinic Acid; Quinolinic Acids; Quisqualic Acid; Radioimmunoassay; Rats; Rats, Inbred Strains | 1990 |
L-Homocysteic acid as an alternative cytotoxin for studying glutamate-induced cellular degeneration of Huntington's disease and normal skin fibroblasts.
Topics: Aspartic Acid; Cell Survival; Cells, Cultured; Cysteic Acid; Cysteine; Fibroblasts; Glutamates; Glutamic Acid; Homocysteine; Humans; Huntington Disease; In Vitro Techniques; Isomerism; Kainic Acid; Kinetics; N-Methylaspartate; Neurotransmitter Agents; Skin; Time Factors | 1985 |
Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Humans; Huntington Disease; Kainic Acid; Mice; N-Methylaspartate; NADH, NADPH Oxidoreductases; NADPH Dehydrogenase; Neurons; Oxadiazoles; Pyridines; Quinolinic Acid; Quinolinic Acids; Quisqualic Acid | 1986 |